Skip to main content
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Kenya Receives 21,000 Doses of Long-Acting HIV Prevention Drug Ahead of March Rollout

  • On February 18, Kenya received an initial consignment of 21,000 starter doses of Lenacapavir, with Health Minister Aden Duale saying, `The first phase of implementation will begin early March, covering 15 counties`.
  • Regulators backed lenacapavir—U.S. Food and Drug Administration approved in June 2025, WHO endorsed in July 2025, and Kenya registered it in January 2026 to support public health goals.
  • Administered twice a year, Lenacapavir reduces transmission risk by more than 99.9% and will cost about Sh7,800 annually, down from roughly $42,000 previously.
  • Dr Patrick Amoth received the shipment with Global Fund partners and U.S. Embassy-Kenya representative Brian Rettman; 12,000 continuation doses are expected by April and the United States Government committed 25,000 more.
  • Eastern and southern Africa account for about 52% of the 40.8 million people living with HIV worldwide, Kenya has an HIV prevalence of 3.7%, and it signed a $2.5 billion bilateral health deal amid aid shifts under President Donald Trump's administration.
Insights by Ground AI

14 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 40% of the sources lean Left, 40% of the sources are Center
40% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Standard broke the news in Nairobi, Kenya on Wednesday, February 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal